NCT02201953 - Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection | Biotech Hunter

Enrollment

558

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

December 31, 2015

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

SOF/VEL

400/100 mg FDC tablet administered orally once daily

DRUG

SOF

400 mg tablet administered orally once daily

DRUG

RBV

Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (76)

2010

Darlinghurst

3004

Melbourne

3065

Fitzroy, Melbourne

3168

Clayton

4064

Brisbane

6000

Perth

6010

Fremantle

8011

Christchurch

12157

Berlin

13008

Marseille

30625

Hanover

31059

Toulouse

40237

Düsseldorf

45122

Hufelandstr

50012

Florence

50932

Cologne

59037

Lille

60590

Frankfurt am Main

63000

Clermont-Ferrand

69004

Lyon

71013

San Giovanni Rotondo

75014

Paris

81377

München

87042

Limoges

90027

Los Angeles

90048

Los Angeles

92110

Clichy

94000

Créteil

94804

Villejuif

Unknown

Sacramento

San Diego

Aurora

Gainesville

Jacksonville

Miami

Orlando

Wellington

Marietta

Chicago

Indianapolis

Lutherville

Boston

Detroit

New York

The Bronx

Durham

Philadelphia

Pittsburgh

Germantown

San Antonio

Norfolk

Richmond

Camperdown

Pessac

Hamburg

Auckland

San Juan

T2N 4Z6

Calgary

T6G 2B7

Edmonton

V5Z 1M9

Vancouver

V6Z 2C7

Vancouver

K1H 8L6

Ottawa

H2X 0A9

Montreal

M5T 2S8

Toronto

D-10969

Berlin

PL6 8DH

Plymouth

PO6 3LY

Portsmouth

G12 0YN

Glasgow

E1 4AT

London

NW3 2PF

London

SE5 9RS

London

SW170QT

London

W2 1NY

London

M8 5RB

Manchester

NG7 2UH

Nottingham

OX3 9DU

Oxford